MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. (Q50777498)

19 March 2018

title

MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. (English)

1 reference

19 March 2018

author

Matti E Waris

5

1 reference

19 March 2018

author name string

Vallittu AM

1

1 reference

19 March 2018

Erälinna JP

2

1 reference

19 March 2018

Ilonen J

3

1 reference

19 March 2018

Salmi AA

4

1 reference

19 March 2018

language of work or name

English

0 references

publication date

13 December 2007

1 reference

19 March 2018

Acta Neurologica Scandinavica

published in

1 reference

19 March 2018

volume

118

1 reference

19 March 2018

issue

1

1 reference

19 March 2018

page(s)

12-17

1 reference

19 March 2018

cites work

Focal cortical dysplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

A whole blood immunoassay for the interferon-inducible human Mx protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: elimination of protease activity of cell lysates in toto.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

The MxA protein levels in whole blood lysates of patients with various viral infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Self-assembly of human MxA GTPase into highly ordered dynamin-like oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Neutralizing antibodies to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2007.00968.X

10.1111/J.1600-0404.2007.00968.X

21 January 2018

Identifiers

DOI

1 reference

19 March 2018

1 reference

19 March 2018